#USA #San Francisco #Foresee Pharmaceuticals #Prostate Cancer #ASCO GU

Foresee Pharmaceuticals to Present at ASCO GU Symposium 2025

Foresee Pharmaceuticals (TPEx: 6576) has made a significant announcement regarding the acceptance of an abstract for presentation at the American Society of Clinical Oncology, Genitourinary (ASCO-GU) Cancers Symposium. This prestigious event will take place at the Moscone Convention Center West in San Francisco, CA, from February 13 to 15, 2025.

The abstract, titled "Global, Phase 3, Open-Label, Single-Arm Studies to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg (Triptorelin Mesylate Injection, 11.25 mg) and FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg) in Patients with Advanced Prostate Cancer (KATANA studies)", underscores the company's commitment to enhancing treatment options for advanced prostate cancer patients.

Foresee's clinical research delves into the efficacy and safety of two long-acting injectable formulations of FP-014—the 11.25 mg formulation administered every three months and the 22.5 mg formulation given every six months. These formulations aim to offer significant benefits to patients by reducing the frequency of injections, ultimately improving patient compliance and quality of life.

Significance of Presentation

Dr. Yisheng Lee, Chief Medical Officer of Foresee, emphasized the importance of this event by stating, "This event gathers the leading minds in urology, oncology, and cancer research to share advancements and insights in the field of prostate cancer."

The abstract's acceptance showcases Foresee's innovative progress within the realm of prostate cancer therapies and adds to its growing reputation within the pharmaceutical field. Dr. Yuhua Li, Chief Technology Officer at Foresee, pointed out this milestone as a demonstration of the potential of Foresee's pioneering SIF-LAI technology across various products and indications. This technology represents a leap forward in the development of enhanced, ready-to-use long-acting injectables.

Dr. Ben Chien, Foresee's Chairman and CEO, expressed enthusiasm for the opportunity to share their research on a global stage, stressing the importance of their upcoming studies. He noted, "We look forward to initiating our studies later this year and recognizing the clear potential for capturing a significant share of the global triptorelin market with FP-014's best-in-class profile."

About FP-014 and Foresee Pharmaceuticals

FP-014 (triptorelin) is a long-acting injectable formulation designed to be administered subcutaneously, significantly reducing the frequency at which patients require treatment. This convenience may lead to better health outcomes for those living with advanced or metastatic prostate cancer, as well as various other conditions including premenopausal breast cancer, endometriosis, and uterine fibroids.

Foresee Pharmaceuticals is a biopharmaceutical company based in Taiwan and the United States, listed on the Taipei Exchange (TPEx 6576). The company's research and development focus on innovative technologies like the Stabilized Injectable Formulation (SIF), which aims to address rare and severe medical conditions. Their current product portfolio includes various advanced stages of clinical development, including CAMCEVI®, which has already received regulatory approval in several regions including the U.S., EU, and Canada.

In conclusion, Foresee Pharmaceuticals' acceptance of its abstract for the ASCO-GU Symposium marks a pivotal moment in its ongoing mission to redefine the treatment landscape for prostate cancer. As research and discussions unfold at this prominent conference, the company anticipates contributing to the vital dialogue surrounding cancer care advancements and strategies to better serve patients globally.